La vendita allo scoperto per Iridex dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Iridex. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Iridex (NASDAQ:IRIX) Azioni, Report sulle vendite allo scoperto

Iridex

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

IRIDEX Corp

Health Care

General

IRIX

Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And wll Be Effective For Services Performed After Nov. 17

WIIM

IRIDEX shares are trading higher. The company reported Q3 financial results.

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $11.58 million which missed the analyst consensus estimate of $12.50 million by 7.35 percent. This is a 9.88 percent decrease over sales of $12.85 million the same period last year.

Earnings

Earnings Misses

News

Iridex Q3 EPS $(0.12) Misses $(0.09) Estimate, Sales $11.58M Miss $12.50M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Iridex will report an earnings per share (EPS) of $-0.09. 
Iridex bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.04, which was followed by a 0.53% drop in the share price the next day.
Here's a look at Iridex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.05</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.21</td>
<td>-0.18</td>
<td>-0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-14.000000000000002%</td>
<td>18.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731341093_0.png" alt="eps graph" />
<h3>Market Performance of Iridex's Stock</h3>
Shares of Iridex were trading at $1.39 as of November 08. Over the last 52-week period, shares are down 27.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IRIX/earnings">To track all earnings releases for Iridex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Iridex's Upcoming Earnings

Management

Iridex Appoints Patrick Mercer As CEO

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $12.631 million which missed the analyst consensus estimate of $12.800 million by 1.32 percent. This is a 1.74 percent decrease over sales of $12.855 million the same period last year.

Iridex Q2 2024 GAAP EPS $(0.16) Misses $(0.11) Estimate, Sales $12.631M Miss $12.800M Estimate

Stifel analyst Thomas Stephan maintains Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) with a Hold and maintains $2 price target.

Price Target

Analyst Ratings

Stifel Maintains Hold on Iridex, Maintains $2 Price Target

IRIDEX shares are trading lower after the company reported worse-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKLI

ARQT

BBLG

BCAB

BOLT

OCEA

OPRX

SINT

VVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 75 percent. This is a 61.54 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $11.76 million which missed the analyst consensus estimate of $12.00 million by 1.99 percent. This is a 14.19 percent decrease over sales of $13.71 million the same period last year.

Iridex Q1 2024 GAAP EPS $(0.21) Misses $(0.12) Estimate, Sales $11.76M Miss $12.00M Estimate

<h3>Gainers</h3>
<ul>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares increased by 73.2% to $1.1 during Thursday's after-market session. The company's market cap stands at $39.3 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 37.85% to $0.08. The market value of their outstanding shares is at $8.2 million. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) stock rose 12.19% to $0.55. The company's market cap stands at $54.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 9.36% to $1.2. The company's market cap stands at $33.0 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 8.73% to $1.12. The market value of their outstanding shares is at $19.0 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares increased by 8.62% to $17.12. The company's market cap stands at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock fell 12.6% to $4.22 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. As per the news, the Q4 earnings report came out today. </li>
<li>Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) stock declined by 12.31% to $0.57. The market value of their outstanding shares is at $92.3 million. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock decreased by 11.37% to $7.72. The company's market cap stands at $425.2 million. The company's, Q4 earnings came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 9.27% to $1.47. The market value of their outstanding shares is at $6.2 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 8.89% to $0.41. The company's market cap stands at $18.8 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock decreased by 8.28% to $2.77. The company's market cap stands at $45.0 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

DARE

PHGE

PLSE

RNAC

SBFM

TLPH

ZNTL

12 Health Care Stocks Moving In Thursday's After-Market Session

IRIDEX shares are trading higher. The company reported Q4 financial results.

<h3>Gainers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 5.52% to $2.65. The company's market cap stands at $43.0 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 22.9% to $0.29 during Tuesday's after-market session. The company's market cap stands at $23.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock fell 11.34% to $1.02. The company's market cap stands at $15.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 9.84% to $1.1. The market value of their outstanding shares is at $40.2 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 7.21% to $3.6. The market value of their outstanding shares is at $4.2 million. </li>
<li>United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares declined by 7.21% to $230.0. The company's market cap stands at $10.8 billion. </li>
<li>ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) stock decreased by 6.46% to $0.58. The market value of their outstanding shares is at $10.0 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

BSGM

CARA

COEP

ESLA

MIRA

TTNP

UTHR

VRPX

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Iridex missed estimated earnings by -260.0%, reporting an EPS of $-0.18 versus an estimate of $-0.05.
Revenue was down $2.74 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 7.000000000000001% increase in the share price the next day.
Here's a look at Iridex's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.17</td>
<td>-0.13</td>
<td>-0.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>13.48M</td>
<td>14.23M</td>
<td>13.64M</td>
<td>15.16M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.85M</td>
<td>12.86M</td>
<td>13.71M</td>
<td>15.20M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Iridex <a href="https://www.benzinga.com/quote/IRIX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Iridex: Q4 Earnings Insights

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.05) by 260 percent. The company reported quarterly sales of $12.458 million which missed the analyst consensus estimate of $14.900 million by 16.39 percent. This is a 18.01 percent decrease over sales of $15.195 million the same period last year.

Iridex Q4 2023 GAAP EPS $(0.18) Misses $(0.05) Estimate, Sales $12.458M Miss $14.900M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
&bull; AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is estimated to report earnings for its fourth quarter.
&bull; Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion.
&bull; GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million.
&bull; Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million.
&bull; BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report earnings for its fourth quarter.
&bull; Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is likely to report quarterly loss at $0.04 per share on revenue of $148.11 million.
&bull; DouYu Intl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $170.91 million.
&bull; Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $94.55 million.
&bull; Forza X1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRZA#NASDAQ">FRZA</a>) is likely to report earnings for its fourth quarter.
&bull; Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is likely to report earnings for its fourth quarter.
&bull; Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is likely to report earnings for its fourth quarter.
&bull; Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is expected to report quarterly loss at $0.51 per share on revenue of $540 thousand.
&bull; Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) is estimated to report earnings for its fourth quarter.
&bull; Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $174.80 million.
&bull; Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is estimated to report earnings for its fourth quarter.
&bull; McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $1.56 billion.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report earnings for its first quarter.
&bull; TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.84 per share on revenue of $14.36 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is estimated to report earnings for its fourth quarter.
&bull; Marpai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAI#NASDAQ">MRAI</a>) is estimated to report earnings for its fourth quarter.
&bull; NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) is likely to report quarterly loss at $0.30 per share on revenue of $3.40 million.
&bull; Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) is projected to report earnings for its fourth quarter.
&bull; Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.
&bull; US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.03 per share on revenue of $8.87 million.
&bull; X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) is likely to report earnings for its fourth quarter.
&bull; Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $14.90 million.
&bull; iPath Series B Carbon Exchange-Traded Notes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRN#NYSE">GRN</a>) is projected to report quarterly loss at $0.01 per share on revenue of $13.40 million.
&bull; Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.64 million.
&bull; BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter.
&bull; GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $2.05 billion.
&bull; Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.10 per share on revenue of $19.57 million.
&bull; Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) is expected to report earnings for its fourth quarter.
&bull; ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) is expected to report quarterly loss at $0.31 per share on revenue of $7.37 million.
&bull; ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) is likely to report earnings for its fourth quarter.
&bull; Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its fourth quarter.
&bull; PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) is projected to report quarterly loss at $1.89 per share on revenue of $1.05 million.
&bull; AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) is likely to report quarterly loss at $1.20 per share on revenue of $100 thousand.
&bull; Velo3D (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) is likely to report quarterly loss at $0.08 per share on revenue of $19.50 million.
&bull; Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is expected to report quarterly earnings at $1.14 per share on revenue of $181.91 million.
&bull; WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) is estimated to report earnings for its fourth quarter.
&bull; LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $34.20 million.
&bull; Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is expected to report earnings for its fourth quarter.
&bull; Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $2.58 per share on revenue of $2.38 billion.
&bull; Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) is likely to report quarterly loss at $0.83 per share on revenue of $24.06 million.
&bull; Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $124.62 million.
&bull; PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $12.62 million.
&bull; Ryvyl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $18.00 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AACG

APTO

BIOR

BLRX

BLUE

BRAG

CGTX

CNXC

DCTH

DOYU

ESLT

FRGE

FRZA

INTZ

KSPI

LIDR

LUXH

MRAI

NCNO

NOAH

OUST

OXBR

PAVM

PAYS

PRGS

RVYL

SIDU

SOAR

USEG

VEEE

Earnings Scheduled For March 26, 2024

Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement.
Analysts estimate that Iridex will report an earnings per share (EPS) of $-0.05. 
Iridex bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 6.84% increase in the share price the next day.
Here's a look at Iridex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.17</td>
<td>-0.13</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-28.000000000000004%</td>
<td>-0.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711382446_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Iridex were trading at $2.56 as of March 22. Over the last 52-week period, shares are up 28.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IRIX/earnings">To track all earnings releases for Iridex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Iridex's Earnings Outlook

Iridex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use". This groundbreaking patent further protects Iridex's intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse&#xAE; devices that utilize the patented technology.&nbsp;&nbsp;
Revolutionizing Eye Care with Precision and Safety The patented technology delivers a state-of-the-art laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond. By employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.
Overcoming Limitations of Current Technologies This innovative MicroPulse technology addresses the limitations of current continuous wave visible lasers. It incorporates advanced software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The system's ability to produce controlled-width pulse trains with reduced power fluctuations represents a novel leap forward in medical laser technology. This technology covers the full laser wavelength range from 520nm-615 nm. In European countries the Unitary Patent will be enforced by members of the Unified Patent Court as well as the United Kingdom.
A Commitment to Advancing Medical Laser Treatments "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," stated David Bruce, President and CEO of Iridex Corporation.

Biotech

Iridex Corporation Receives European Patent On MicroPulse Technology EP 3009093, Entitled "Laser System With Short Pulse Characteristics And Its Methods Of Use"

IRIDEX GAAP EPS of $0.16 beats by $0.28, revenue of $12.6M misses by $0.2M

IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript

Iridex Frustrates, But Expect A Transaction By Year-End

IRIDEX files to sell 4.95M shares of common stock for holders

Iridex appoints Patrick Mercer as CEO

Iridex ( ($IRIX) ) has issued an announcement. IRIDEX Corporation has announced the appointment of Patrick Mercer as the new CEO and President, eff...

Iridex Announces New CEO and Strategic Leadership Changes

IRIDEX GAAP EPS of -$0.12, revenue of $11.58M

An announcement from Iridex ( ($IRIX) ) is now available. In a significant leadership change, Dave Bruce was terminated as CEO on October 1, 2024, ...

Iridex Leadership Changes and Strategic Appointments

IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript

Iridex (IRIX) confirms that Local Coverage Determination) L37531, relating to Micro-Invasive Glaucoma Surgery, MIGS, was adopted as scheduled and w...

Comments

Iridex

Vendite allo scoperto

Iridex (NASDAQ:IRIX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO